Results 121 to 130 of about 585,966 (213)

Targeting Bruton tyrosine kinase with acalabrutinib attenuates murine sclerodermatous chronic graft versus host disease. [PDF]

Front Immunol
Raguraman V, Mysinger M, Verma M, Mohiyuddin S, Jabbour N, Kesler M, Joshi T, Palaniyandi S, Hildebrandt GC.   +8 more
europepmc   +1 more source

Infectious adverse events associated with novel Bruton tyrosine kinase (BTK) inhibitors in adults with chronic lymphocytic leukaemia: A meta-analysis of randomized controlled trials. [PDF]

Br J Haematol
Janc JJ, Wróbel T, Feliniak N, Kalicińska E.   +3 more
europepmc   +1 more source

Bruton tyrosine kinase inhibitors in combination with chemoimmunotherapy is an effective treatment for patients with Richter's syndrome. [PDF]

Leuk Res Rep
Meier T, Huynh G, Ayala E, Tun HW, Iqbal M.   +4 more
europepmc   +1 more source

Role of Bruton's Tyrosine Kinase in B Cell Development

Clinical and Developmental Immunology, 2001
Alex Maas, Rudolf W. Hendriks
doaj   +1 more source

Bruton Tyrosine Kinase Inhibitor Ibrutinib and Pericardial Tamponade: A Case Report. [PDF]

Cureus
Baptista M, Soares M, Lima R, Ferreira C, Gregório T.   +4 more
europepmc   +1 more source

Bruton Tyrosine Kinase Inhibition in Combination With Bispecific Antibodies for Richter's Syndrome: A Report of Two Cases and Mini Review. [PDF]

Cureus
Hane BC, Hoffmann M, Zhang D, Chopra S, Bennett J.   +4 more
europepmc   +1 more source

Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: What Are the Current Options? [PDF]

Eur J Haematol
Caserta S, Martino EA, Vigna E, Bruzzese A, Amodio N, Lucia E, Olivito V, Labanca C, Mendicino F, Morabito F, Gentile M.   +10 more
europepmc   +1 more source

Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor. [PDF]

J Clin Oncol
Eyre TA, Song Y, Hermine O, Shuang Y, Jurczak W, Farias JS, Mahuad C, Özcan M, Jachimowicz RD, Chen T, Ivanova E, Li X, Man G, Bourquelot P, Vezan R, Wang M.   +15 more
europepmc   +1 more source

Third-Generation Bruton tyrosine kinase Inhibitors for the Treatment of Monoclonal Gammopathy of Thrombotic Significance (MGTS). [PDF]

Am J Hematol
Man L, Kanack AJ, Mauch EE, Splinter NP, Padmanabhan A.   +4 more
europepmc   +1 more source

Long-term outcomes and treatment patterns in Waldenström macroglobulinemia patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy. [PDF]

Blood Cancer J
Chohan KL, Gensini L, Seif S, Sun X, Feng L, Becnel MR, Gaballa MM, Lee HC, Pasvolsky O, Patel KK, Ye JC, Weber DM, Orlowski RZ, Thomas SK.   +13 more
europepmc   +1 more source